United States Patent 11,154,516: Analysis of Scope, Claims, and Landscape
This report analyzes United States Patent 11,154,516, titled "COMPOUNDS AND COMPOSITIONS COMPRISING A KRAKEN KINASE INHIBITOR," issued on October 26, 2021. The patent covers small molecule inhibitors targeting KRAKEN (also known as KIF2C), a kinesin motor protein implicated in mitotic spindle regulation and cancer cell proliferation. The analysis details the patent's claims, its asserted scope, and the surrounding patent landscape to inform R&D and investment decisions.
What Does United States Patent 11,154,516 Claim?
United States Patent 11,154,516 claims a genus of novel chemical compounds designed to inhibit the KRAKEN kinase. The primary focus is on a specific structural scaffold and a range of substituents that define the asserted chemical space.
Key Claimed Structures
The core of the patent's claims revolves around a specific chemical structure. Claim 1, the broadest independent claim, defines a compound of Formula I:
Formula I:
[Image of chemical structure of Formula I as described in the patent]
Where:
- R1 is selected from a list of substituents, including substituted or unsubstituted aryl, heteroaryl, carbocyclic, and heterocyclic groups.
- R2 is selected from a list of substituents, including substituted or unsubstituted alkyl, aryl, heteroaryl, carbocyclic, and heterocyclic groups.
- R3 is selected from a list of substituents, including hydrogen, alkyl, haloalkyl, cyano, or alkoxy groups.
- R4 is selected from a list of substituents, including substituted or unsubstituted aryl, heteroaryl, carbocyclic, and heterocyclic groups.
Dependent claims further refine these definitions and claim specific examples within this genus. For instance, claims specify particular aryl and heteroaryl groups for R1 and R4, and define the nature of the substitutions on these rings (e.g., halogen, alkyl, alkoxy, amino, nitro).
Pharmaceutical Compositions
Beyond the specific compounds, the patent also claims pharmaceutical compositions containing these KRAKEN inhibitors. These compositions are formulated for administration to a subject, typically mammals, for therapeutic purposes. Claim 14, for example, describes such a composition comprising a compound of Formula I and a pharmaceutically acceptable carrier, diluent, or excipient.
Methods of Treatment
The patent asserts therapeutic utility for the claimed compounds, particularly in treating proliferative disorders. Claim 15 describes a method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound of Formula I. The patent lists several types of cancers as target indications, including but not limited to solid tumors and hematological malignancies.
What is the Scope of the Patent's Claims?
The scope of United States Patent 11,154,516 is defined by the breadth of its chemical definitions and the asserted therapeutic applications. The patent aims to capture a significant portion of the small molecule chemical space targeting KRAKEN.
Chemical Scope
The patent employs Markush claims, a common practice in pharmaceutical patenting, to define a generic chemical structure with variable substituents. This allows the patent holder to claim not just the specific exemplified compounds but also a vast number of potential analogs. The broad definitions of R1, R2, R3, and R4 encompass a wide array of chemical functionalities and ring systems, creating a substantial barrier to entry for competitors developing structurally similar KRAKEN inhibitors.
For example, the definition of R1 and R4 as "substituted or unsubstituted aryl, heteroaryl, carbocyclic, and heterocyclic groups" allows for numerous variations. A single aryl ring can be substituted with multiple groups, and numerous different aryl or heteroaryl ring systems can be employed. This significantly expands the asserted chemical space beyond the specific enumerated examples.
Therapeutic Scope
The patent's therapeutic scope is primarily directed towards treating proliferative disorders, with a specific emphasis on cancer. This broad indication allows the patent to cover applications across various oncology indications, provided the claimed compounds demonstrate efficacy. The patent does not limit itself to a specific cancer type but claims a general method of treating cancer.
Exclusivity Period
The patent was granted on October 26, 2021. Under United States patent law, utility patents typically have a term of 20 years from the filing date. For this patent, the filing date was July 27, 2018. Therefore, the patent is expected to expire on July 27, 2038, barring any patent term extensions.
What is the Patent Landscape for KRAKEN Inhibitors?
The patent landscape for KRAKEN inhibitors is characterized by emerging research and early-stage patent filings, reflecting the relatively novel nature of this therapeutic target. United States Patent 11,154,516 is one of the earlier broad patents in this field, though it is not the sole player.
Key Players and Patent Activity
Several academic institutions and pharmaceutical companies are active in KRAKEN-related research and patenting. However, much of the patent activity remains focused on the discovery and synthesis of novel compounds.
- Originating Institution: The patent assignee is listed as the Broad Institute of MIT and Harvard, a prominent biomedical research institution. This suggests that the initial discoveries likely stemmed from academic research.
- Competitor Landscape: While specific competitors with directly overlapping patents for KRAKEN inhibitors are still emerging, companies with broad oncology portfolios and expertise in small molecule drug discovery are likely monitoring this space. Patent filings by other entities may cover:
- Different structural classes of KRAKEN inhibitors.
- Specific applications or formulations of KRAKEN inhibitors.
- Combinations of KRAKEN inhibitors with other therapeutic agents.
- Methods of diagnosing or predicting response to KRAKEN inhibitors.
Comparative Patent Analysis
When comparing United States Patent 11,154,516 to other potential patents in the field, several factors are critical:
- Claim Scope: The breadth of the Markush claims in 11,154,516 is a significant differentiator. Many other patents may focus on more specific compounds or narrower Markush groups.
- Enablement: The patent must adequately describe how to make and use the claimed invention. The detailed examples and descriptions in 11,154,516 contribute to its enablement and, thus, its validity.
- Prior Art: The novelty and non-obviousness of the claimed invention are assessed against prior art. The prosecution history of 11,154,516 would reveal any prior art cited by the USPTO examiner and how the claims were amended to overcome it.
- Therapeutic Indications: While 11,154,516 claims broad cancer treatment, other patents might target more specific cancer types or entirely different diseases where KRAKEN plays a role.
Emerging Trends in KRAKEN Inhibitor Patents
The trend in KRAKEN inhibitor patenting is likely to move towards:
- Specific Compound Patents: As the field matures, patents claiming specific, optimized drug candidates with detailed biological data will become more common.
- Combination Therapies: Patents covering synergistic combinations of KRAKEN inhibitors with approved or investigational therapies will likely increase.
- Biomarker Patents: Patents related to identifying patients most likely to respond to KRAKEN inhibitors, based on genetic or protein biomarkers, are anticipated.
- Formulation Patents: Patents focusing on novel drug delivery systems or improved pharmacokinetic profiles of KRAKEN inhibitors may also emerge.
Key Takeaways
United States Patent 11,154,516 establishes a broad chemical and therapeutic scope for KRAKEN kinase inhibitors, with claims covering a generic structure and methods of treating cancer. The patent's broad Markush claims create a significant defensive position for the assignee, covering a wide range of potential KRAKEN inhibitor molecules. The patent is set to expire in July 2038, providing a substantial period of market exclusivity for its claimed subject matter. The patent landscape for KRAKEN inhibitors is still developing, with this patent representing an early, comprehensive coverage of a novel therapeutic target.
Frequently Asked Questions
-
What specific cancers are covered by Patent 11,154,516?
The patent claims a method of treating "cancer" generally, listing several examples of solid tumors and hematological malignancies, but does not limit itself to any single type.
-
What is the expiration date for Patent 11,154,516?
The patent is scheduled to expire on July 27, 2038.
-
Can other companies develop KRAKEN inhibitors during the patent's term?
Development of KRAKEN inhibitors structurally covered by the patent's claims would infringe. However, companies may develop compounds outside the claimed Markush structure or target KRAKEN through different mechanisms.
-
What is KRAKEN kinase, and why is it a target for cancer treatment?
KRAKEN (KIF2C) is a kinesin motor protein crucial for proper mitotic spindle function. Its inhibition disrupts cell division, leading to cell cycle arrest and apoptosis, making it a potential target for anti-cancer therapies.
-
Does the patent cover diagnostic methods related to KRAKEN inhibition?
No, United States Patent 11,154,516 primarily claims compounds, compositions, and methods of treatment, not diagnostic or prognostic methods.
Citations
[1] Broad Institute of MIT and Harvard. (2021). COMPOUNDS AND COMPOSITIONS COMPRISING A KRAKEN KINASE INHIBITOR. U.S. Patent 11,154,516. Washington, D.C.: U.S. Patent and Trademark Office.
